Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 19/20 | 0.50 |
| ▸ | F2 | P00734 | 6/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.43 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.43 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29237602 | 1.00 | F10 (0.50) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL27276124 | 0.88 | F10 (0.48) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL30285603 | 0.88 | F10 (0.53) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL30967772 | 0.88 | F10 (0.48) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL30285660 | 0.85 | F10 (0.46) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL29336700 | 0.85 | F10 (0.46) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL29336712 | 0.85 | F10 (0.46) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL29336749 | 0.83 | F10 (0.44) | F10F2PRSS1PRSS2PRSS3 | |
| SCHEMBL31108591 | 0.83 | ALDH1A1 (0.38) | F10 | |
| SCHEMBL27382327 | 0.82 | TRPA1 (0.36) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240279220-A1 | INDOLE COMPOUNDS AND METHODS OF USE | SIONNA THERAPEUTICS INC. | 2024-08-22 | — | — | US | disclosed |
| EP-4396179-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION (US) | 2024-07-10 | — | — | EP | disclosed |
| CN-118201919-A | Indole compounds and methods of use | 健赞公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2023034992-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION (US) | 2023-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240279220-A1 | INDOLE COMPOUNDS AND METHODS OF USE | CFTR, INMT, IDO1 | F10 3750/4885F2 2919/4885PRSS1 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.